KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Gilead Sciences (GILD) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $400.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 1900.0% year-over-year to $400.0 million, compared with a TTM value of $590.0 million through Dec 2025, down 86.02%, and an annual FY2025 reading of $590.0 million, down 85.95% over the prior year.
  • Asset Writedowns and Impairment was $400.0 million for Q4 2025 at Gilead Sciences, up from $190.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.7 billion in Q1 2022 and bottomed at $20.0 million in Q4 2024.
  • Average Asset Writedowns and Impairment over 4 years is $1.1 billion, with a median of $400.0 million recorded in 2025.
  • The sharpest move saw Asset Writedowns and Impairment crashed 60.0% in 2024, then surged 1900.0% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $2.7 billion in 2022, then crashed by 98.15% to $50.0 million in 2023, then plummeted by 60.0% to $20.0 million in 2024, then soared by 1900.0% to $400.0 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for GILD at $400.0 million in Q4 2025, $190.0 million in Q2 2025, and $20.0 million in Q4 2024.